- Conditions
- Prostate Cancer - Recurrent
- Interventions
- HDR Brachytherapy + EBRT + STAD
- Drug
- Lead sponsor
- Loyola University
- Other
- Eligibility
- 18 Years to 99 Years · Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Maywood, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 431
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Amenorrhea, Premature Ovarian Failure, Ovarian Function Insufficiency
- Interventions
- Leuprolide Acetate, Questionnaire, Hematopoietic Stem Cell Transplantation
- Drug · Behavioral · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 40 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer, Advanced Prostate Cancer, Hormone Sensitive Prostate Cancer
- Interventions
- Darolutamide, Relugolix
- Drug
- Lead sponsor
- Atish Choudhury, MD
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer, Breast Cancer - Female, Breast Cancer - Male
- Interventions
- Tamoxifen, Ribociclib, Goserelin
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Prostate Cancer
- Interventions
- Exisulind, luteinizing hormone-releasing hormone (LHRH) agonist, Antiandrogen
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2011
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Precocious, Leuprolide Acetate, Luteinizing Hormone (LH), Gonadotrophin-releasing Hormone Agonist (GnRHa), Tanner Staging, Depot Formulation, Suppression of LH, Central Precocious Puberty (CPP), Gonadotrophin-releasing Hormone (GnRH), Lupron, GnRH Analog, Pediatrics Central Precocious Puberty
- Interventions
- Leuprolide Acetate 3 Month Depot
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- Not listed
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Long Beach, California • Los Angeles, California + 13 more
- Conditions
- Prostate Cancer
- Interventions
- Degarelix, Leuprolide
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- Male only
- Enrollment
- 545 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 42 more
- Conditions
- Cardiovascular Risk Factor
- Interventions
- No to Low Endogenous Estrogen, Estradiol
- Other
- Lead sponsor
- University of Delaware
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Newark, Delaware
- Conditions
- Breast Cancer
- Interventions
- goserelin, letrozole, leuprolide acetate, conventional surgery
- Drug · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Prostate Cancer
- Interventions
- Casodex, Eulexin, LHRH agonist, radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years · Male only
- Enrollment
- 1,579 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2022
- U.S. locations
- 241
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 181 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Ribociclib + Letrozole OR Fulvestrant, Palbociclib + Letrozole OR Fulvestrant, Paclitaxel +/- Tislelizumab
- Drug
- Lead sponsor
- SOLTI Breast Cancer Research Group
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 26
- States / cities
- Clearwater, Florida • Coral Gables, Florida • Hollywood, Florida + 22 more
- Conditions
- Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Mantle Cell Lymphoma
- Interventions
- Leuprolide acetate depot (LAD) 11.25 mg 3 Month, Matched placebo
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 4
- States / cities
- St Louis, Missouri • New York, New York • Durham, North Carolina + 1 more
- Conditions
- Musculoskeletal Injury, Hypogonadism, Hormonal Contraception
- Interventions
- Goserelin 3.6 MG, Multi-Stressor Training, Testosterone gel (AndroGel 5g), Testosterone gel (AndroGel 1.25g)
- Drug · Other
- Lead sponsor
- Bradley Nindl
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Prostate Cancer
- Interventions
- Flutamide (Eulexin) and Lupron or Zoladex, External Beam Radiotherapy
- Drug · Radiation
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 41 Years and older · Male only
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- HER2 Negative Breast Cancer
- Interventions
- Ribociclib 400mg, Letrozole 2.5mg, Anastrazole 1mg, Goserelin 3.6 MG, Adjuvant chemotherapy
- Drug · Radiation
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Interventions
- Abiraterone Acetate, Bicalutamide, Biospecimen Collection, Computed Tomography Angiography, Leuprolide, Prednisone, Radiation Therapy, Relugolix
- Drug · Procedure · Radiation
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia
- Conditions
- Prostate Cancer Metastatic
- Interventions
- EMD 525797, Placebo, Standard of Care (SoC)
- Drug · Other
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 12
- States / cities
- Pleasant Hill, California • Chicago, Illinois • New Orleans, Louisiana + 9 more
- Conditions
- Prostate Cancer
- Interventions
- Relugolix, Leuprorelin
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • San Diego, California • Denver, Colorado + 16 more
- Conditions
- Cancer, Prostate Neoplasms
- Interventions
- goserelin with dutasteride, goserelin with bicalutamide and dutasteride, goserelin with bicalutamide and dutasteride and ketoconazole
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Prostatic Neoplasms
- Interventions
- Apalutamide, Bicalutamide, Bicalutamide Placebo, Apalutamide Placebo, GnRH (agonist), 74-80 Grays (units of radiation)
- Drug · Radiation
- Lead sponsor
- Aragon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,503 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 60
- States / cities
- Homewood, Alabama • Chandler, Arizona • Scottsdale, Arizona + 57 more
- Conditions
- Kallmann Syndrome, Hypogonadotropic Hypogonadism, GnRH Deficiency
- Interventions
- gonadotropin releasing hormone (GnRH)
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 624 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1989 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Adenocarcinoma of the Prostate, Stage IV Prostate Cancer
- Interventions
- AT-101, Bicalutamide, LHRH agent
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Ann Arbor, Michigan • New Brunswick, New Jersey + 1 more
- Conditions
- Prostatic Neoplasms
- Interventions
- Abemaciclib, Darolutamide, LHRH agonist/antagonist
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 3
- States / cities
- Springdale, Arkansas • Mineola, New York • New York, New York
- Conditions
- Castrate Sensitive Prostate Cancer
- Interventions
- goserelin, Enzalutamide, Abiraterone, 18F-DCFPyL, Prednisone, Radical Prostatectomy
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland